Design and Development of Innovative Bi-Specific Antibodies
In this webinar we introduce therapeutic antibodies, focusing on the opportunities and challenges of current monotherapy. We analyze the major benefits of bispecific antibodies and the current formats used in clinical trails. Additionally, we share an in-depth, integrated SMAB (single-domain antibody fused to monoclonal antibody) case study from rational design to preclinical development.
Dr. Li Chen
Associate Director of Discovery, ProBio
Li Chen, Ph.D, Senior Project Manager, ProBio. Dr. Chen received his Ph.D. from the University of Massachusetts Medical School, specializing in antigen Engeneering, Dr. Chen has extensive experience in Antibody drug discovery, he has published over 8 highly-cited papers in immunology, virology, and biochemistry Journals, and has received few patents in the antibody discovery field.
BS of Bioinformatics from Zhejiang University of China; PhD training of immunology from University of Massachusetts Medical School. After joining GenScript, Dr. Chen is in charge of the antibody drug discovery services, and has more than 10 years’ experience in immunology, antibody drug discovery and engineering, managing over 300 antibody drug discovery/engineering projects.
BS of Bioinformatics from Zhejiang University of China; PhD training of immunology from University of Massachusetts Medical School. After joining GenScript, Dr. Chen is in charge of the antibody drug discovery services, and has more than 10 years’ experience in immunology, antibody drug discovery and engineering, managing over 300 antibody drug discovery/engineering projects.
ProBio SMABody(Single-domain antibody fused to monoclonal Ab) platform naturally combine the single domain antibody and the monoclonal antibody to make a bispecific antibody in symmetric format with good biological efficacy and good developability.
| Anti-idiotype antibody generation and applications in antibody drug discovery | ||
|---|---|---|
| Anti-idiotypic Antibody Service | DNA Immunization Service | Therapeutic Hybridoma Development |
|
|
|